Article
PARP1 catalytic domain mutations drive high-level resistance to saruparib while preserving DNA damage response vulnerabilities
2026-05-13
Abstract excerpt
Clinical poly (ADP)-ribose polymerase (PARP) inhibitors (PARPi) are limited by toxicities associated with inhibition of multiple PARP family proteins and acquired resistance. As PARP1-specific inhibitors, like saruparib (AZD5305), move toward standard-of-care status for BRCA and HR-deficient cancers replacing less specific PARPi, defining mechanisms of intrinsic and acquired resistance is essential for developing...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4b7bf4c2-a502-51ab-a5f1-b869b19fd1ac
- DOI
- 10.64898/2026.05.08.723870
